Wegovy

Adjunct to reduced-calorie diet & increased physical activity for wt management, including wt loss & maintenance, in adults w/ initial BMI of ≥30 kg/m², or ≥27 to <30 kg/m² in the presence of at least 1 wt-related comorbidity eg, dysglycaemia (prediabetes or type 2 DM), HTN, dyslipidaemia, obstructive sleep apnoea or CV disease; to reduce risk of major adverse CV events (CV death, non-fatal MI or stroke) in adults w/ established CV disease & either obese or overwt. Adjunct to reduced-calorie diet & increased physical activity for wt management in adolescents ≥12 yr w/ obesity & body wt >60 kg.

SC Inj in the abdomen, thigh or upper arm. Dose escalation: Initially 0.25 mg once wkly (wk 1-4), increased to 0.5 mg once wkly after 4 wk (wk 5-8), then 1 mg once wkly (wk 9-12), & further increased to 1.7 mg once wkly (wk 13-16) to a maintenance dose of 2.4 mg once wkly.

May be taken with or without food.

Hypersensitivity.

Not to be administered IV or IM. Discontinue use if pancreatitis is suspected & not to be restarted if confirmed. Not a substitute for insulin in patients w/ type 2 diabetes. Not recommended in patients w/ type 2 diabetes w/ uncontrolled or potentially unstable diabetic retinopathy; type 1 diabetes; CHF NYHA Class IV. Acute pancreatitis. Increased risk of hypoglycaemia in combination w/ sulfonylurea or insulin; developing diabetic retinopathy complications in patients w/ diabetic retinopathy. Potential risk of dehydration in relation to GI side effects. Avoid fluid depletion. Patients w/ inflammatory bowel disease; diabetic gastroparesis; history of pancreatitis. Closely monitor patients w/ diabetic retinopathy. Not recommended to use w/ other products for wt management. Not to be used in combination w/ other GLP-1 receptor agonists. Avoid hypoglycaemia while driving & using machines when used in combination w/ sulfonylurea or insulin. Dizziness may occur which may affect ability to drive & use machines. Not recommended in patients w/ severe renal impairment (eGFR <30 mL/min/1.73 m²), including patients w/ ESRD; severe hepatic impairment. Mild or moderate hepatic impairment. Women of childbearing potential must use contraception while on treatment. Not to be used during pregnancy & breast-feeding. Discontinue treatment if pregnancy occurs; atleast 2 mth before planned pregnancy. Childn <12 yr. Elderly ≥75 yr.

Headache; vomiting, diarrhoea, constipation, nausea, abdominal pain; fatigue. Hypoglycaemia in patients w/ type 2 diabetes; dizziness, dysgeusia; diabetic retinopathy in patients w/ type 2 diabetes; gastritis, GERD, dyspepsia, eructation, flatulence, abdominal distension; cholelithiasis; hair loss; inj site reactions.

Delayed gastric emptying time & potential influence on absorption of concomitantly administered oral medicinal products. Decreased INR w/ acenocoumarol. Frequent INR monitoring w/ warfarin or other coumarin derivatives.

Antidiabetic Agents

A10BJ06 - semaglutide ; Belongs to the class of glucagon-like peptide-1 (GLP-1) analogues. Used in the treatment of diabetes.

S